Many biotechs are in the green in early trade after the U.S. House of Representatives voted in favor of the Senate's version of "right to try" legislation yesterday. The bill, expected to be quickly signed into law by President Trump, will allow people with life-threatening illnesses to obtain unapproved drugs that have been vetted for safety in early-stage studies. In other words, the federal government will not interfere with a person's efforts to gain access to such a drug in this situation.
Critics say the law, which does not guarantee access the medications, will not have any appreciable effect on the status quo since supplies of investigational drugs are limited because developers earmark them for clinical trials.
Selected tickers: (CRSP +7.3%)(EDIT +4.8%)(NTLA +5.2%)(UTHR +1.6%)(PBYI +1.9%)(BMRN +2.2%)(BIIB +1.1%)(CELG +0.8%)(XBI +0.9%)(BIB +0.9%)(ADVM +2.5%)(ABEO +1.4%)(RCKT +1.5%)(QURE +9.4%)(VYGR +2.8%)(RARE +0.8%)(SGMO +2.2%)(ONCE +4.6%